Approval enables European launch of a faster, simpler, cost-effective ESG procedure

CAESAREA, Israel, Nov. 6, 2025 /PRNewswire/ -- Nitinotes Ltd., a medical device company transforming the treatment of obesity, today announced it has received CE Mark approval for the EndoZip™ System, the first fully automated suturing platform for endoscopic sleeve gastroplasty (ESG). The milestone clearance enables Nitinotes to begin commercialization across the European Union and other CE Mark-accepting markets.

Obesity is one of the most urgent global health challenges, affecting more than 650 million adults worldwide. Current treatment pathways leave a significant gap between medical management such as GLP-1 therapy and invasive bariatric surgery. ESG is emerging as a minimally invasive alternativ

See Full Page